Previous 10 | Next 10 |
Sends Letter to Fellow Stockholders Detailing the Board’s Record of Persistent Value Erosion and Highlights Pathway to Unlock Tremendous Upside Potential Cites Lack of Alignment with Stockholders, Poor Corporate Governance, Entrenchment Tactics and Strategic Misma...
FLORENCE, Italy and BOSTON, June 06, 2022 (GLOBE NEWSWIRE) -- The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) today announced the presentation at the 2022 American Society of Clinical...
Urges Stockholders to Vote “FOR” Radius’ Highly Qualified, Independent Director Nominees – Catherine J. Friedman, Jean-Pierre Garnier, Ph.D. and Andrew C. von Eschenbach, M.D. – on the BLUE Proxy Card Details Company’s Signif...
Radius Health (NASDAQ:RDUS) is ending development of the abaloparatide transdermal system, a patch version of its osteoporosis injection Tymlos, after the U.S. FDA said an additional pivotal trial is necessary. Shares are down 6% in after-hours trading. The company said a new trial ...
Company ascertained regulatory clarity for possible forward progression of abalo-TDS Additional and successful clinical trial would be required to advance towards an NDA filing New timeline for earliest possible abalo-TDS launch: 2H 2025 Based on regulatory clarity, timeline, ...
Further Expands Board’s Expertise and Gender Diversity Enhances Corporate Governance BOSTON, May 20, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today announced that it has added two new independent members to the Board of...
Elacestrant, an oncologic under development from Radius Health (NASDAQ:RDUS) for ER+/HER2- breast cancer, met its primary endpoint of progression-free survival ("PFS") in a phase 3 trial. Radius Health (RDUS) shares are up 6% in after-hours trading. The EMERALD trial enrolled patien...
EMERALD study met both its primary end points of progression-free survival (PFS) in overall population and in ESR1 mutated patients PFS rate at 12 months with elacestrant was 22.3% vs. 9.4% with SOC in the overall population, and 26.8% vs. 8.2% in the ESR1 mutation population Da...
Gainers: Celularity CELU +10%. Purple Biotech (PPBT) +8%. BioSig Technologies (BSGM) +4%. Concert Pharmaceuticals (CNCE) +4%. Molecular Partners (MOLN) +4%. Losers: Baudax Bio BXRX -28%. Doximity DOCS -9%. Radius Health (RDUS) -7%. N...
The following slide deck was published by Radius Health, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Radius Health, Inc. 2022 Q1 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...
A look at the top 10 most actives in the United States Ocean Power Technologies Inc. (OPTT) rose 54.4% to $0.4264 on volume of 158,036,142 shares Versus Systems Inc. (VS) rose 73.5% to $2.29 on volume of 40,036,424 shares Tesla Inc. (TSLA) rose 5.3% to $220.97 on volume of 32,375,487 shar...
Ferrous, Nonferrous and Finished Steel Sales Volumes Up Sequentially Radius Board Declares Quarterly Dividend PORTLAND, Ore., July 02, 2024 (GLOBE NEWSWIRE) -- Radius Recycling, Inc. (NASDAQ: RDUS) today reported results for the third quarter of fiscal 2024 ended May 31, 2024. ...